StemCell Institute (7096) AI Stock Analysis

• Market Cap: ¥10.82B
• Dividend Yield: N/A
• Average Volume (3M): 48.62K
• Price to Earnings (P/E): 28.0
• Beta (1Y): 0.44
• Revenue Growth: 7.98%
• EPS Growth: 24.12%
• Country: JP
• Employees: 98
• Sector: Healthcare
• Sector Strength: 58
• Industry: Biotechnology
• EPS (TTM): 4.49
• Shares Outstanding: 10,246,600
• 10 Day Avg. Volume: 90,200
• 30 Day Avg. Volume: 48,616
• PEG Ratio: 1.47
• Price to Book (P/B): 5.29
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.37K
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 67 Neutral
• Price Target: ¥1,218.00 ▲(15.34%Upside)

StemCell Institute's strong financial performance and profitability are the primary strengths. However, technical analysis indicates a lack of momentum, and the high P/E ratio suggests potential overvaluation. The absence of dividend yield and negative free cash flow are concerns that slightly dampen the overall score.

StemCell Institute Business Overview & Revenue Model

Company Description

StemCell Institute (7096) is a biotechnology company specializing in the research and development of stem cell therapies. The company operates in the healthcare sector, focusing on the advancement of regenerative medicine. Its core services include providing clinical-grade stem cell products for therapeutic applications, conducting clinical trials, and offering consulting services in stem cell research and therapy development.

How the Company Makes Money

StemCell Institute makes money through several key revenue streams. The company generates income by selling clinical-grade stem cell products to healthcare providers and research institutions. Additionally, it earns revenue by conducting clinical trials and licensing its proprietary technologies to pharmaceutical companies. The company may also form strategic partnerships with other biotech firms to co-develop stem cell therapies, sharing both costs and profits. Consulting services in the field of stem cell research and development further contribute to its earnings.

StemCell Institute Financial Statement Overview

Summary

StemCell Institute demonstrates strong financial performance with robust revenue growth and profitability, supported by solid margins. The balance sheet is stable with low debt, but negative free cash flow suggests cash management challenges.

Income Statement

StemCell Institute shows strong revenue growth with a 7.97% increase from the previous year. The gross profit margin is robust at 63.16%, and the net profit margin has improved to 14.40%, indicating efficient cost management and profitability. The EBIT and EBITDA margins of 15.62% and 25.94% respectively, reflect solid operational efficiency.

Balance Sheet

The company maintains a healthy balance sheet with a low debt-to-equity ratio of 0.20, showcasing financial stability. The equity ratio of 35.02% suggests a strong capital structure. However, the return on equity is moderate at 14.68%, indicating potential for improved profitability.

Cash Flow

Operating cash flow to net income ratio is strong at 1.21, indicating good cash generation relative to net income. However, the free cash flow has turned negative, indicating potential challenges in cash management. The decrease in free cash flow from the previous year is a concern, suggesting a need for better capital expenditure management.

Breakdown
TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement		Total Revenue
2.64B	2.68B	2.48B	2.09B	1.78B	1.41B
	Gross Profit
1.66B	1.69B	1.58B	1.34B	1.11B	924.21M
	EBIT
415.52M	418.51M	413.76M	297.56M	226.95M	86.88M
	EBITDA
512.27M	695.19M	534.00M	383.89M	309.47M	119.66M
	Net Income Common Stockholders
395.00M	385.80M	310.98M	198.03M	133.73M	62.37M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
2.85B	3.20B	2.85B	3.32B	3.51B	2.74B
	Total Assets
6.54B	7.50B	6.54B	5.81B	5.22B	3.96B
	Total Debt
8.78M	518.96M	8.78M	5.89M	0.00	0.00
	Net Debt
-2.84B	-2.68B	-2.84B	-3.32B	-3.51B	-2.74B
	Total Liabilities
3.85B	4.87B	3.85B	3.51B	3.11B	2.64B
	Stockholders Equity
2.69B	2.63B	2.69B	2.30B	2.10B	1.32B
Cash Flow		Free Cash Flow
0.00	-10.11M	132.97M	39.77M	264.81M	-164.34M
	Operating Cash Flow
0.00	467.69M	334.63M	99.67M	469.29M	239.00M
	Investing Cash Flow
0.00	-259.08M	-811.77M	-285.10M	404.17M	-520.26M
	Financing Cash Flow
0.00	146.70M	-1.33M	-869.00K	644.37M	0.00

StemCell Institute Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1056.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7096, the sentiment is Negative. The current price of 1056 is below the 20-day moving average (MA) of 1113.75, below the 50-day MA of 1220.58, and below the 200-day MA of 1435.78, indicating a bearish trend. The MACD of -54.32 indicates Negative momentum. The RSI at 39.39 is Neutral, neither overbought nor oversold. The STOCH value of 48.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7096.

StemCell Institute Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4880	68 Neutral	¥14.30B	284.55		0.69%	-13.57%	-106.11%
7096	67 Neutral	¥10.82B	28.03		―	7.98%	24.12%
7774	58 Neutral	¥24.53B	―		―	-2.34%	-278.32%
Sector *	54 Neutral	$5.37B	3.26	-45.10%	3.30%	16.81%	0.02%
7776	51 Neutral	¥18.03B	―		―	-4.04%	-0.88%
4978	49 Neutral	¥17.72B	173.73		―	8.46%	49.97%
4599	47 Neutral	¥21.19B	―		―	-100.00%	-1079.89%